Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Ramucirumab (Cyramza) + capecitabine or 5-FU + cisplatin for gastric cancer of GOJ – treatment naive for palliative chemotherapy	5-Fluorouracil , Capecitabine (Xeloda) , Cisplatin (Platinol) , Ramucirumab (Cyramza)	Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2017	View \| Download
Pembrolizumab in addition to cisplatin and fluorouracil for recurrent locally advanced or metastatic oesophageal cancer – First-line	5-Fluorouracil , Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475)	Oesophageal cancer	Head and Neck Cancer	2019	View \| Download
Nivolumab in combination with cisplatin and fluorouracil for oesophageal cancer – first-line	5-Fluorouracil , Cisplatin (Platinol) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Oesophageal cancer	Head and Neck Cancer	2019	View \| Download
Durvalumab with fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer	5-Fluorouracil , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Leucovorin , Oxaliplatin	Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2023	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications